Comparison of Surgical Versus Transcatheter Aortic Valve Replacement for Patients With Aortic Stenosis at Low-Intermediate Risk

Authors

Mahin R Khan
Waleed T Kayani
Malalai Manan
Ahmad Munir
Ihab Hamzeh
Salim S Virani
Yochai Birnbaum
Hani Jneid
Mahboob Alam

Publication Date

4-1-2020

Journal

Cardiovascular Diagnosis and Therapy

DOI

10.21037/cdt.2020.02.11

PMID

32420093

PMCID

PMC7225446

PubMedCentral® Posted Date

4-10-2020

PubMedCentral® Full Text Version

Post-print

Published Open-Access

yes

Keywords

Transcatheter aortic valve replacement (TAVR), surgical aortic valve replacement (SAVR), low-intermediate risk

Abstract

BACKGROUND: To compare safety and efficacy of transcatheter aortic valve replacement (TAVR) with surgical aortic valve replacement (SAVR) in patients at low-intermediate risk, given the paucity of robust data.

METHODS: We performed an aggregate data meta-analysis of 7 randomized controlled trials (RCTs) and 6,778 patients comparing TAVR with SAVR for aortic stenosis (AS) in low-intermediate risk patients (Society of Thoracic Surgeons risk-score ≤8%) using the random-effects model. Primary outcome was all-cause mortality at 30-day, 1-year and 2-year of follow-up. Secondary outcomes included cardiac-mortality, stroke, acute kidney injury (AKI), atrial fibrillation (AF), permanent pacemaker (PPM) implantation, major-bleeding, moderate-severe paravalvular regurgitation (PVR) and rehospitalization.

RESULTS: All-cause mortality, cardiac-mortality and stroke were comparable between the two groups. AF was higher with SAVR at 30-day [odds ratio (OR) 0.17, 95% confidence intervals (CI): 0.12-0.24] thorough to 2-year (OR 0.34, 95% CI: 0.21-0.55), while PPM implantation was higher with TAVR (30-day: OR 3.31, 95% CI: 1.64-6.66, 2-year: OR 3.17, 95% CI: 1.02-9.86). Moderate-severe PVR was more prevalent with TAVR at all follow-ups. On inter-group comparison, patients in the low-risk group had an even lower risk of AF, but a higher risk of PPM implantation as compared to the patients in the intermediate-risk group undergoing TAVR.

CONCLUSIONS: Compared to SAVR, TAVR had comparable all-cause mortality and stroke, lower-risk of AF, but was associated with a higher risk of PPM implantation and moderate-severe PVR in low-intermediate-risk patients. Thus, highlighting the need for longer-term follow-up before robust inferences are drawn.